Clinical and non-clinical use of MDMA.
Tidsskr Nor Laegeforen June 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al.
Clinical and non-clinical use of MDMA.
Ivar W Goksøyr
6 papers in the library · 24 citations · publishing 2022-2026
Papers
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study - CORRIGENDUM.
Br J Psychiatry February 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial
Journal of Psychiatric Research November 27, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Joanna Róg et al. 3 citations
BACKGROUND: Major depressive disorder (MDD) is a leading cause of global disability, and current treatments often fail to provide sustained effectiveness. MDMA-assisted therapy (MDMA-AT) is a promising treatment for MDD. However, the long-term effects are not known. OBJECTIVES: To examine the long-term effects of MDMA-AT for MDD. METHODS: Twelve participants with MDD and an ongoing moderate to...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.
The British journal of psychiatry : the journal of mental science July 11, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al. 6 citations
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic stress disorder, but has not been investigated for a primary diagnosis of major depressive disorder (MDD). We aimed to explore the proof of principle and safety as a first study with MDMA-AT for MDD, and to provide preliminary efficacy data. Twelve...
A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.
Journal of psychopharmacology (Oxford, England) June 10, 2025 Torsten Passie, Anja Loizaga-Velder, Alicia Danforth et al. 4 citations
The authors offer a model for curriculum for education and training in substance-assisted psychotherapy (SAP), that is, psychedelic, psycholytic, and entactogen/MDMA (3,4-methylenedioxymethamphetamine)-assisted psychotherapy, addressing both the detailed contents of training and the question of experiential training. All authors of this model have an abiding interest and extensive experience in...
Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”
Frontiers in Psychiatry October 26, 2022 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al. 11 citations
Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the...